Financial Data and Key Metrics Changes - For the first three quarters of 2025, total revenue reached CNY 2.57 billion, a year-on-year increase of 23.1, while net profit attributable to ordinary shareholders was approximately CNY 410 million, rising 51.9% compared to the same period last year [1] - In Q3, total revenue was CNY 975 million, marking a year-on-year growth of 38.4, with operating profit nearly CNY 114 million, a substantial year-on-year increase of 329.8% [21][24] - Net profit attributable to ordinary shareholders in Q3 reached CNY 158 million, up 60.1% year-on-year [24] Business Segment Data and Key Metrics Changes - The insurtech business generated an operating profit of about CNY 180 million in Q3, a year-on-year increase of 44.3% [1] - Insurance-related revenue reached about CNY 870 million, increasing by 44.8% year-on-year and 17.8% quarter-on-quarter [7] - Profiling service fees stood at around CNY 65.66 million, remaining stable year-on-year, while digital clinical trial solutions contributed over CNY 31.85 million, with a year-on-year increase of 31.3% [22] Market Data and Key Metrics Changes - The medical profiling platform has raised medical campaigns for a cumulative total of 3.61 million patients as of the end of Q3 [2] - The digital clinical trial solution business enrolled over 1,000 patients in a single quarter, demonstrating robust growth momentum [2][17] - The eFind platform extended its collaboration network by partnering with 216 pharmaceutical and contract research organizations [17] Company Strategy and Development Direction - The company is focused on leveraging AI technologies to drive integration and innovation across operations, fueling sustainable long-term growth [5] - Waterdrop C-Point AI was launched as a low-code AI platform to empower employees in building tailored solutions for various tasks [3] - The company is exploring applications of AI in non-insurance areas to support growth [3] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in exceeding full-year revenue and profit guidance, supported by robust business performance [5] - The company emphasized the importance of refined management while achieving scale growth [25] - Management highlighted the ongoing investment in AI and its impact on operational efficiency and decision-making [12][13] Other Important Information - The company completed its fourth cash dividend distribution since IPO, totaling around $10.9 million [5] - By the end of November 2025, approximately 58.1 million ADS had been repurchased in the open market, totaling $113 million [5] - The company updated its ESG measures and released the 2024 annual ESG report, enhancing its governance framework [4] Q&A Session Summary - No specific questions and answers were provided in the content, thus this section is not applicable.

Financial Data and Key Metrics Changes - For the first three quarters of 2025, total revenue reached CNY 2.57 billion, a year-on-year increase of 23.1, while net profit attributable to ordinary shareholders was approximately CNY 410 million, rising 51.9% compared to the same period last year [1] - The company reported total revenue of CNY 975 million for the third quarter, marking a year-on-year growth of 38.4 [13] - Operating profit for the quarter was nearly CNY 114 million, reflecting a substantial year-over-year increase of 329.8%, with net profit attributable to ordinary shareholders reaching CNY 158 million, up 60.1% year-over-year [15] Business Line Data and Key Metrics Changes - The insurtech business achieved an operating profit of about CNY 180 million in the quarter, a year-on-year increase of 44.3% [1] - Insurance-related revenue reached approximately CNY 870 million, increasing by 44.8% year-on-year and 17.8% quarter-on-quarter, with an operating profit margin of 20.3% [4] - Profiling service fees stood at around CNY 65.66 million, remaining stable year-on-year, while digital clinical trial solutions contributed over CNY 31.85 million, with a year-on-year increase of 31.3% [14] Market Data and Key Metrics Changes - As of September 30, 2025, the cumulative registrations for the medical profiling platform reached approximately 485 million, with a total of CNY 71.2 billion raised for 3.61 million patients [9] - The digital clinical trial solution income in the third quarter reached CNY 31.85 million, marking a 31.3% year-on-year increase [12] Company Strategy and Development Direction - The company is focused on leveraging advancing AI technologies to drive integration and innovation across operations, aiming for sustainable long-term growth [4] - The launch of Waterdrop C-Point AI, a low-code AI platform, is intended to empower employees to build and deploy tailored solutions for various tasks, supporting growth in both insurance and non-insurance areas [2] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in exceeding full-year revenue and profit guidance, emphasizing the importance of AI in enhancing operational efficiency and decision-making [4] - The company highlighted its commitment to sustainable development and creating value for society through its various initiatives [2] Other Important Information - The company has filed 69 patent applications centered on large language models, including nine international filings, indicating a strong focus on innovation [2] - As of the end of November 2025, the company had repurchased approximately 58.1 million ADS in the open market, totaling $113 million [3] Q&A Session Summary Question: What are the key drivers of growth in the insurance business? - The insurance business maintained significant growth momentum, with optimized real-time identification capabilities and enhanced integration of data links among advertising, operation, and risk control systems [4] Question: How is the company addressing operational efficiency? - The deployment of AI across various services has significantly improved operational efficiency, with AI medical insurance experts boosting productivity and response times [7][8]